{
    "info": {
        "nct_id": "NCT03850574",
        "official_title": "A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)",
        "inclusion_criteria": "Inclusion Criteria for Parts A/B/C:\n\n* Study participant is defined as having morphologically documented primary or secondary AML, MDS-IB2 (≥ 10% bone marrow blasts), or CMML by the World Health Organization (WHO) criteria (2016), and fulfills one of the following:\n\n  1. Refractory to at least 1 cycle of prior therapy\n  2. Relapsed after achieving remission with a prior therapy\n* Study participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Study participant's interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), at 4 weeks for biologic or cellular immunotherapies, or least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT). Upon discussion with the Medical Monitor, a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies.\n* Study participant must meet the following criteria as indicated on the clinical laboratory tests.\n\n  1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3× institutional upper limit normal (ULN)\n  2. Total serum bilirubin ≤ 1.5× institutional ULN\n  3. Creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of > 45 mL/min.\n* Study participant is suitable for oral administration of study drug and has minimum life expectancy (≥ 3 months)\n* Female study participants must be either:\n* Of non-childbearing potential\n\n  1. Post-menopausal (defined as at least 1 year without any menses) prior to screening, or\n  2. Documented surgically sterile or status post hysterectomy (at least 1 month prior to screening)\n* Or, if of childbearing potential,\n\n  1. Must have a negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment), and\n  2. Must use an acceptable highly effective method of birth control starting at screening and throughout the study period and for 90 days after the final study drug administration.\n* Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration\n* Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.\n* Male study participants and their female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.\n* Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.\n* Study participant agrees not to participate in another interventional study while on treatment.\n\nExclusion Criteria for Parts A/B/C:\n\nStudy participants must not enter the study if any of the following exclusion criteria are met:\n\n* Study participant was diagnosed with acute promyelocytic leukemia (APL).\n* Study participant has known BCR-ABL-positive leukemia.\n* Study participant has an active malignancy other than AML, MDS-IB2, or CMML.\n* Study participant has persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)\n* Study participant has had hematopoietic stem cell transplant (HSCT) and meets any of the following criteria:\n\n  1. Has undergone HSCT within the 2-month period prior to the first study dose\n  2. Has clinically significant graft-versus-host-disease (GVHD) requiring treatment\n  3. Has ≥ Grade 2 persistent non-hematological toxicity related to the transplant\n  4. Had a donor lymphocyte infusion (DLI) ≤ 30 days prior to the first study dose.\n* Study participant has meningeal or central nervous system (CNS) involvement with leukemia or other CNS disease related to underlying and secondary effects of malignancy.\n* Study participant has disseminated intravascular coagulation abnormality (DIC).\n* Study participant has had major surgery within 4 weeks prior to the first study dose.\n* Study participant has had radiation therapy within 4 weeks prior to the first study dose.\n* Study participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or study participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.\n* Study participant has any of the following cardiac abnormalities of history:\n\n  1. Study participant has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250 milliseconds (ms).\n  2. Study participant has a mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements.\n  3. Study participant has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT, syndrome, family history of long QT syndrome.\n* Study participant is known to have active infection including any identified active COVID-19 infection.\n* Study participant is known to have human immunodeficiency virus infection.\n* Study participant has known active hepatitis B or C, or other active hepatic disorder.\n* Study participant has any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation.\n* Study participant has a history of Grade 3 or 4 non-hematologic toxicity related to tyrosine kinase inhibitor.\n\nInclusion Criteria for Part D:\n\n* Study participant is defined as having morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016) and considered ineligible to receive intensive chemotherapy.\n\nStudy participants ≥ 75 years of age are considered ineligible to receive intensive chemotherapy if they meet any of the following criteria:\n\n1. ECOG Performance Status of 2 or 3;\n2. Cardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction ≤ 50% or chronic stable angina;\n3. Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume during the first second (FEV1) ≤ 65%;\n4. Creatinine clearance ≥ 30 mL/min to < 45 ml/min;\n5. Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0×ULN;\n6. Any other comorbidity that the Investigator judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor during screening and prior to treatment.\n\nStudy participants are considered ineligible to receive intensive chemotherapy based on their age being ≥ 75 years.\n\n* Study participant < 75 years has an ECOG performance status ≤ 2; study participant ≥ 75 years has an ECOG performance status 0-2.\n* Study participant must meet the following criteria as indicated on the clinical laboratory tests:\n\n  1. Serum AST and ALT ≤ 3× institutional ULN unless considered due to leukemic organ involvement.\n  2. Total serum bilirubin ≤ 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years; total serum bilirubin ≤ 1.5x institutional ULN (or ≤ 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants ≥ 75 years.\n  3. Creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 30 mL/min for study participants < 75 years; creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 45 mL/min for study participants ≥ 75 years.\n* Study participant is suitable for oral administration of study drug and has minimum life expectancy (≥ 3 months)\n* Female study participants must be either:\n* Of non-childbearing potential\n\n  1. Post-menopausal (defined as at least 1 year without any menses) prior to screening, or\n  2. Documented surgically sterile or status post hysterectomy (at least 1 month prior to screening)\n* Or, if of childbearing potential,\n\n  1. Must have a negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment), and\n  2. Must use an acceptable highly effective contraception starting at screening and throughout the study period and for 90 days after the final study drug administration.\n* Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration.\n* Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.\n* Male study participants and their female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.\n* Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.\n* Study participant agrees not to participate in another interventional study while on treatment.\n\nExclusion Criteria for Part D:\n\nStudy participants must not enter the study if any of the following exclusion criteria are met:\n\n* Study participant was diagnosed with acute promyelocytic leukemia (APL).\n* Study participant has known BCR-ABL-positive leukemia.\n* Study participant has an active malignancy other than AML.\n* Study participant has received treatment with the following:\n\n  1. An HMA, VEN (or other BCL-2 inhibitor), a tyrosine kinase inhibitor (TKI), a FLT3 inhibitor (FLT3i), a hematopoietic stem cell transplant (HSCT), and/or a chemotherapeutic agent for antecedent myeloid neoplasm (Note: Prior chemotherapy for solid tumors considered in remission is allowed.)\n  2. CAR-T cell therapy\n  3. Experimental therapies for antecedent myeloid neoplasms\n  4. Current participation in another research or observational study\n* Study participant has persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery).\n* Study participant has meningeal or central nervous system (CNS) involvement with leukemia or other CNS disease related to underlying and secondary effects of malignancy.\n* Study participant has disseminated intravascular coagulation abnormality (DIC).\n* Study participant has had major surgery within 4 weeks prior to the first study dose.\n* Study participant has had radiation therapy within 4 weeks prior to the first study dose.\n* Study participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or study participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.\n* Study participant has any of the following cardiac abnormalities of history:\n\n  1. Study participant has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250 milliseconds (ms).\n  2. Study participant has a mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements.\n  3. Study participant has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT, syndrome, family history of long QT syndrome.\n* Study participant is known to have active infection, including any identified active COVID-19 infection.\n* Study participant is known to have human immunodeficiency virus infection.\n* Study participant has known active hepatitis B or C, or other active hepatic disorder.\n* Study participant has any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation, including a chronic respiratory disease that requires continuous oxygen, or a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, or cardiovascular disease, or any other medical condition or known hypersensitivity to any of the study medications including excipients of VEN and AZA that in the opinion of the Investigator would adversely affect participating in this study.\n* Study participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal) or other medical conditions (e.g., infection, heart failure, COPD flare, etc.).\n* Study participant has a white blood cell count > 25 × 10^9/L. (Treatment with hydroxyurea or use of leukapheresis are permitted to meet this criterion.)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Study participant has a white blood cell count > 25 × 10^9/L. (Treatment with hydroxyurea or use of leukapheresis are permitted to meet this criterion.)",
                "criterions": [
                    {
                        "exact_snippets": "white blood cell count > 25 × 10^9/L",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "white blood cell count > 25 × 10^9/L",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Post-menopausal (defined as at least 1 year without any menses) prior to screening, or",
                "criterions": [
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Of non-childbearing potential",
                "criterions": [
                    {
                        "exact_snippets": "Of non-childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "potential",
                            "expected_value": "non-childbearing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Of non-childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "potential",
                            "expected_value": "non-childbearing"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Or, if of childbearing potential,",
                "criterions": [
                    {
                        "exact_snippets": "if of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "if of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female study participants must be either:",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Female study participants",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Relapsed after achieving remission with a prior therapy",
                "criterions": [
                    {
                        "exact_snippets": "Relapsed after achieving remission with a prior therapy",
                        "criterion": "disease status after prior therapy",
                        "requirement": {
                            "requirement_type": "remission achieved with prior therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Relapsed after achieving remission with a prior therapy",
                        "criterion": "disease status after prior therapy",
                        "requirement": {
                            "requirement_type": "relapse after remission",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Relapsed after achieving remission with a prior therapy",
                        "criterion": "disease status after prior therapy",
                        "requirement": {
                            "requirement_type": "remission achieved with prior therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Relapsed after achieving remission with a prior therapy",
                        "criterion": "disease status after prior therapy",
                        "requirement": {
                            "requirement_type": "relapse after remission",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3× institutional upper limit normal (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Serum aspartate aminotransferase (AST) ... ≤ 3× institutional upper limit normal (ULN)",
                        "criterion": "serum aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional upper limit normal (ULN)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) ≤ 3× institutional upper limit normal (ULN)",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional upper limit normal (ULN)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum aspartate aminotransferase (AST) ... ≤ 3× institutional upper limit normal (ULN)",
                        "criterion": "serum aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional upper limit normal (ULN)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) ≤ 3× institutional upper limit normal (ULN)",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional upper limit normal (ULN)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of > 45 mL/min.",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance as calculated by the Cockcroft-Gault formula ... > 45 mL/min",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance ... measured by 24-h urine collection of > 45 mL/min",
                        "criterion": "creatinine clearance (24-h urine collection)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Creatinine clearance as calculated by the Cockcroft-Gault formula ... > 45 mL/min",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance ... measured by 24-h urine collection of > 45 mL/min",
                        "criterion": "creatinine clearance (24-h urine collection)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Total serum bilirubin ≤ 1.5× institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "Total serum bilirubin ≤ 1.5× institutional ULN",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "institutional ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total serum bilirubin ≤ 1.5× institutional ULN",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "institutional ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant's interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), at 4 weeks for biologic or cellular immunotherapies, or least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT). Upon discussion with the Medical Monitor, a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies.",
                "criterions": [
                    {
                        "exact_snippets": "interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells)",
                        "criterion": "interval from prior cytotoxic agent treatment to study drug administration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells)",
                        "criterion": "interval from prior cytotoxic agent treatment to study drug administration",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "hydroxyurea given for controlling blast cells"
                        }
                    },
                    {
                        "exact_snippets": "interval from prior treatment to time of study drug administration is ... at 4 weeks for biologic or cellular immunotherapies",
                        "criterion": "interval from prior biologic or cellular immunotherapy to study drug administration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "interval from prior treatment to time of study drug administration is ... least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT)",
                        "criterion": "interval from prior experimental or noncytotoxic agent (including immunosuppressive therapy post-HSCT) to study drug administration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies",
                        "criterion": "recovery from prior therapy toxicity",
                        "requirement": {
                            "requirement_type": "toxicity_grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies",
                        "criterion": "recovery from prior therapy toxicity",
                        "requirement": {
                            "requirement_type": "recovery_from_clinically_relevant_safety_issue",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells)",
                                                "criterion": "interval from prior cytotoxic agent treatment to study drug administration",
                                                "requirement": {
                                                    "requirement_type": "duration",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 2,
                                                        "unit": "weeks"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells)",
                                                "criterion": "interval from prior cytotoxic agent treatment to study drug administration",
                                                "requirement": {
                                                    "requirement_type": "exception",
                                                    "expected_value": "hydroxyurea given for controlling blast cells"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "interval from prior treatment to time of study drug administration is ... at 4 weeks for biologic or cellular immunotherapies",
                                        "criterion": "interval from prior biologic or cellular immunotherapy to study drug administration",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "interval from prior treatment to time of study drug administration is ... least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT)",
                                        "criterion": "interval from prior experimental or noncytotoxic agent (including immunosuppressive therapy post-HSCT) to study drug administration",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 5,
                                                "unit": "half-lives"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies",
                                "criterion": "recovery from prior therapy toxicity",
                                "requirement": {
                                    "requirement_type": "recovery_from_clinically_relevant_safety_issue",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "a shorter than stated washout period may be considered provided that the study participant has recovered from any clinically relevant safety issue and recovered to Grade ≤ 1 toxicity from prior therapies",
                                "criterion": "recovery from prior therapy toxicity",
                                "requirement": {
                                    "requirement_type": "toxicity_grade",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Refractory to at least 1 cycle of prior therapy",
                "criterions": [
                    {
                        "exact_snippets": "Refractory to at least 1 cycle of prior therapy",
                        "criterion": "refractoriness to prior therapy",
                        "requirement": {
                            "requirement_type": "number of prior therapy cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Refractory to at least 1 cycle of prior therapy",
                        "criterion": "refractoriness to prior therapy",
                        "requirement": {
                            "requirement_type": "refractory status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Refractory to at least 1 cycle of prior therapy",
                        "criterion": "refractoriness to prior therapy",
                        "requirement": {
                            "requirement_type": "number of prior therapy cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Refractory to at least 1 cycle of prior therapy",
                        "criterion": "refractoriness to prior therapy",
                        "requirement": {
                            "requirement_type": "refractory status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Must use an acceptable highly effective method of birth control starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "starting at screening and throughout the study period and for 90 days after the final study drug administration",
                        "criterion": "birth control method usage duration",
                        "requirement": {
                            "requirement_type": "start_time",
                            "expected_value": "screening"
                        }
                    },
                    {
                        "exact_snippets": "starting at screening and throughout the study period and for 90 days after the final study drug administration",
                        "criterion": "birth control method usage duration",
                        "requirement": {
                            "requirement_type": "end_time",
                            "expected_value": "90 days after the final study drug administration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must use an acceptable highly effective method of birth control",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "starting at screening and throughout the study period and for 90 days after the final study drug administration",
                        "criterion": "birth control method usage duration",
                        "requirement": {
                            "requirement_type": "start_time",
                            "expected_value": "screening"
                        }
                    },
                    {
                        "exact_snippets": "starting at screening and throughout the study period and for 90 days after the final study drug administration",
                        "criterion": "birth control method usage duration",
                        "requirement": {
                            "requirement_type": "end_time",
                            "expected_value": "90 days after the final study drug administration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Or, if of childbearing potential,",
                "criterions": [
                    {
                        "exact_snippets": "if of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "if of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Study participant has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT, syndrome, family history of long QT syndrome.",
                "criterions": [
                    {
                        "exact_snippets": "any factors that increase the risk of QTc prolongation",
                        "criterion": "risk factors for QTc prolongation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk factors for arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT, syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any factors that increase the risk of QTc prolongation",
                        "criterion": "risk factors for QTc prolongation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk factors for arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT, syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Study participant has a mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements.",
                "criterions": [
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "value in three successive screening measurements",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "value in three successive screening measurements",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Documented surgically sterile or status post hysterectomy (at least 1 month prior to screening)",
                "criterions": [
                    {
                        "exact_snippets": "Documented surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "sterile"
                        }
                    },
                    {
                        "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                        "criterion": "hysterectomy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post hysterectomy"
                        }
                    },
                    {
                        "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                        "criterion": "hysterectomy",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Documented surgically sterile",
                                "criterion": "surgical sterility",
                                "requirement": {
                                    "requirement_type": "documentation",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Documented surgically sterile",
                                "criterion": "surgical sterility",
                                "requirement": {
                                    "requirement_type": "status",
                                    "expected_value": "sterile"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                                "criterion": "hysterectomy",
                                "requirement": {
                                    "requirement_type": "status",
                                    "expected_value": "post hysterectomy"
                                }
                            },
                            {
                                "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                                "criterion": "hysterectomy",
                                "requirement": {
                                    "requirement_type": "time since procedure",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "month"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant must meet the following criteria as indicated on the clinical laboratory tests.",
                "criterions": [
                    {
                        "exact_snippets": "clinical laboratory tests",
                        "criterion": "clinical laboratory test results",
                        "requirement": {
                            "requirement_type": "meets study criteria",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "clinical laboratory tests",
                        "criterion": "clinical laboratory test results",
                        "requirement": {
                            "requirement_type": "meets study criteria",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has known BCR-ABL-positive leukemia.",
                "criterions": [
                    {
                        "exact_snippets": "known BCR-ABL-positive leukemia",
                        "criterion": "BCR-ABL-positive leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known BCR-ABL-positive leukemia",
                        "criterion": "BCR-ABL-positive leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant agrees not to participate in another interventional study while on treatment.",
                "criterions": [
                    {
                        "exact_snippets": "agrees not to participate in another interventional study while on treatment",
                        "criterion": "participation in another interventional study",
                        "requirement": {
                            "requirement_type": "absence during treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "agrees not to participate in another interventional study while on treatment",
                        "criterion": "participation in another interventional study",
                        "requirement": {
                            "requirement_type": "absence during treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. CAR-T cell therapy",
                "criterions": [
                    {
                        "exact_snippets": "CAR-T cell therapy",
                        "criterion": "CAR-T cell therapy",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "CAR-T cell therapy",
                        "criterion": "CAR-T cell therapy",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Current participation in another research or observational study",
                "criterions": [
                    {
                        "exact_snippets": "Current participation in another research or observational study",
                        "criterion": "participation in another research or observational study",
                        "requirement": {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current participation in another research or observational study",
                        "criterion": "participation in another research or observational study",
                        "requirement": {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has any of the following cardiac abnormalities of history:",
                "criterions": [
                    {
                        "exact_snippets": "any of the following cardiac abnormalities of history",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "any of the following cardiac abnormalities of history",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has an active malignancy other than AML, MDS-IB2, or CMML.",
                "criterions": [
                    {
                        "exact_snippets": "active malignancy other than AML, MDS-IB2, or CMML",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active malignancy other than AML, MDS-IB2, or CMML",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 0,
                                "unit": "AML, MDS-IB2, or CMML"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "active malignancy other than AML, MDS-IB2, or CMML",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active malignancy other than AML, MDS-IB2, or CMML",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 0,
                                "unit": "AML, MDS-IB2, or CMML"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Experimental therapies for antecedent myeloid neoplasms",
                "criterions": [
                    {
                        "exact_snippets": "Experimental therapies for antecedent myeloid neoplasms",
                        "criterion": "experimental therapies for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": "experimental therapies"
                        }
                    },
                    {
                        "exact_snippets": "Experimental therapies for antecedent myeloid neoplasms",
                        "criterion": "experimental therapies for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "disease context",
                            "expected_value": "antecedent myeloid neoplasms"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Experimental therapies for antecedent myeloid neoplasms",
                        "criterion": "experimental therapies for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": "experimental therapies"
                        }
                    },
                    {
                        "exact_snippets": "Experimental therapies for antecedent myeloid neoplasms",
                        "criterion": "experimental therapies for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "disease context",
                            "expected_value": "antecedent myeloid neoplasms"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has any of the following cardiac abnormalities of history:",
                "criterions": [
                    {
                        "exact_snippets": "any of the following cardiac abnormalities of history",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "any of the following cardiac abnormalities of history",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Has undergone HSCT within the 2-month period prior to the first study dose",
                "criterions": [
                    {
                        "exact_snippets": "Has undergone HSCT within the 2-month period prior to the first study dose",
                        "criterion": "HSCT (hematopoietic stem cell transplantation)",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has undergone HSCT within the 2-month period prior to the first study dose",
                        "criterion": "HSCT (hematopoietic stem cell transplantation)",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant was diagnosed with acute promyelocytic leukemia (APL).",
                "criterions": [
                    {
                        "exact_snippets": "diagnosed with acute promyelocytic leukemia (APL)",
                        "criterion": "acute promyelocytic leukemia (APL) diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "diagnosed with acute promyelocytic leukemia (APL)",
                        "criterion": "acute promyelocytic leukemia (APL) diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Study participant has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT, syndrome, family history of long QT syndrome.",
                "criterions": [
                    {
                        "exact_snippets": "any factors that increase the risk of QTc prolongation",
                        "criterion": "risk factors for QTc prolongation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk factors for arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT, syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any factors that increase the risk of QTc prolongation",
                        "criterion": "risk factors for QTc prolongation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk factors for arrhythmic events",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT, syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal) or other medical conditions (e.g., infection, heart failure, COPD flare, etc.).",
                "criterions": [
                    {
                        "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "requires therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other medical conditions (e.g., infection, heart failure, COPD flare, etc.)",
                        "criterion": "other medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                                "criterion": "systemic infection",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                                "criterion": "systemic infection",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)",
                                "criterion": "systemic infection",
                                "requirement": {
                                    "requirement_type": "requires therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "other medical conditions (e.g., infection, heart failure, COPD flare, etc.)",
                        "criterion": "other medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Documented surgically sterile or status post hysterectomy (at least 1 month prior to screening)",
                "criterions": [
                    {
                        "exact_snippets": "Documented surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "sterility_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                        "criterion": "history of hysterectomy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                        "criterion": "history of hysterectomy",
                        "requirement": {
                            "requirement_type": "time since hysterectomy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Documented surgically sterile",
                                "criterion": "surgical sterility",
                                "requirement": {
                                    "requirement_type": "documentation",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Documented surgically sterile",
                                "criterion": "surgical sterility",
                                "requirement": {
                                    "requirement_type": "sterility_status",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                                "criterion": "history of hysterectomy",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "status post hysterectomy (at least 1 month prior to screening)",
                                "criterion": "history of hysterectomy",
                                "requirement": {
                                    "requirement_type": "time since hysterectomy",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "month"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation.",
                "criterions": [
                    {
                        "exact_snippets": "any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation",
                        "criterion": "any condition (per Investigator's opinion)",
                        "requirement": {
                            "requirement_type": "suitability for study participation",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation",
                        "criterion": "any condition (per Investigator's opinion)",
                        "requirement": {
                            "requirement_type": "suitability for study participation",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is known to have human immunodeficiency virus infection.",
                "criterions": [
                    {
                        "exact_snippets": "known to have human immunodeficiency virus infection",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known to have human immunodeficiency virus infection",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is known to have active infection including any identified active COVID-19 infection.",
                "criterions": [
                    {
                        "exact_snippets": "known to have active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any identified active COVID-19 infection",
                        "criterion": "active COVID-19 infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known to have active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any identified active COVID-19 infection",
                        "criterion": "active COVID-19 infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has disseminated intravascular coagulation abnormality (DIC).",
                "criterions": [
                    {
                        "exact_snippets": "disseminated intravascular coagulation abnormality (DIC)",
                        "criterion": "disseminated intravascular coagulation (DIC)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "disseminated intravascular coagulation abnormality (DIC)",
                        "criterion": "disseminated intravascular coagulation (DIC)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has known BCR-ABL-positive leukemia.",
                "criterions": [
                    {
                        "exact_snippets": "known BCR-ABL-positive leukemia",
                        "criterion": "BCR-ABL-positive leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known BCR-ABL-positive leukemia",
                        "criterion": "BCR-ABL-positive leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Study participant has a mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements.",
                "criterions": [
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "number of measurements",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "successive screening measurements"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "mean QT interval (QTc) by Friderica's method (QTcF) > 450 ms in three successive screening measurements",
                        "criterion": "mean QT interval (QTc) by Friderica's method (QTcF)",
                        "requirement": {
                            "requirement_type": "number of measurements",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "successive screening measurements"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female study participants must be either:",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Female study participants",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant was diagnosed with acute promyelocytic leukemia (APL).",
                "criterions": [
                    {
                        "exact_snippets": "diagnosed with acute promyelocytic leukemia (APL)",
                        "criterion": "acute promyelocytic leukemia (APL) diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "diagnosed with acute promyelocytic leukemia (APL)",
                        "criterion": "acute promyelocytic leukemia (APL) diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0×ULN;",
                "criterions": [
                    {
                        "exact_snippets": "Moderate hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "total bilirubin > 1.5 to ≤ 3.0×ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Moderate hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "moderate"
                        }
                    },
                    {
                        "exact_snippets": "total bilirubin > 1.5 to ≤ 3.0×ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has had major surgery within 4 weeks prior to the first study dose.",
                "criterions": [
                    {
                        "exact_snippets": "has had major surgery within 4 weeks prior to the first study dose",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "has had major surgery within 4 weeks prior to the first study dose",
                            "criterion": "major surgery",
                            "requirement": {
                                "requirement_type": "recency",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 4,
                                    "unit": "weeks prior to the first study dose"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has received treatment with the following:",
                "criterions": [
                    {
                        "exact_snippets": "Study participant has received treatment",
                        "criterion": "prior treatment",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Study participant has received treatment",
                        "criterion": "prior treatment",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Of non-childbearing potential",
                "criterions": [
                    {
                        "exact_snippets": "Of non-childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "non-childbearing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Of non-childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "non-childbearing"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has meningeal or central nervous system (CNS) involvement with leukemia or other CNS disease related to underlying and secondary effects of malignancy.",
                "criterions": [
                    {
                        "exact_snippets": "meningeal or central nervous system (CNS) involvement with leukemia",
                        "criterion": "meningeal or CNS involvement with leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other CNS disease related to underlying and secondary effects of malignancy",
                        "criterion": "CNS disease related to underlying and secondary effects of malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "meningeal or central nervous system (CNS) involvement with leukemia",
                        "criterion": "meningeal or CNS involvement with leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other CNS disease related to underlying and secondary effects of malignancy",
                        "criterion": "CNS disease related to underlying and secondary effects of malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Had a donor lymphocyte infusion (DLI) ≤ 30 days prior to the first study dose.",
                "criterions": [
                    {
                        "exact_snippets": "Had a donor lymphocyte infusion (DLI) ≤ 30 days prior to the first study dose.",
                        "criterion": "donor lymphocyte infusion (DLI)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to the first study dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Had a donor lymphocyte infusion (DLI) ≤ 30 days prior to the first study dose.",
                        "criterion": "donor lymphocyte infusion (DLI)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to the first study dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is known to have active infection, including any identified active COVID-19 infection.",
                "criterions": [
                    {
                        "exact_snippets": "known to have active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any identified active COVID-19 infection",
                        "criterion": "active COVID-19 infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known to have active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any identified active COVID-19 infection",
                        "criterion": "active COVID-19 infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has had radiation therapy within 4 weeks prior to the first study dose.",
                "criterions": [
                    {
                        "exact_snippets": "has had radiation therapy within 4 weeks prior to the first study dose",
                        "criterion": "radiation therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "has had radiation therapy within 4 weeks prior to the first study dose",
                        "criterion": "radiation therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Study participant has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250 milliseconds (ms).",
                "criterions": [
                    {
                        "exact_snippets": "clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (rhythm, conduction, morphology)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "clinical importance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "third-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    },
                    {
                        "exact_snippets": "second-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "second"
                        }
                    },
                    {
                        "exact_snippets": "PR interval > 250 milliseconds (ms)",
                        "criterion": "PR interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                                "criterion": "resting ECG",
                                "requirement": {
                                    "requirement_type": "abnormality (rhythm, conduction, morphology)",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                                "criterion": "resting ECG",
                                "requirement": {
                                    "requirement_type": "clinical importance",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "third-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    },
                    {
                        "exact_snippets": "second-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "second"
                        }
                    },
                    {
                        "exact_snippets": "PR interval > 250 milliseconds (ms)",
                        "criterion": "PR interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has meningeal or central nervous system (CNS) involvement with leukemia or other CNS disease related to underlying and secondary effects of malignancy.",
                "criterions": [
                    {
                        "exact_snippets": "meningeal or central nervous system (CNS) involvement with leukemia",
                        "criterion": "meningeal or CNS involvement with leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other CNS disease related to underlying and secondary effects of malignancy",
                        "criterion": "CNS disease related to underlying and secondary effects of malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "meningeal or central nervous system (CNS) involvement with leukemia",
                        "criterion": "meningeal or CNS involvement with leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other CNS disease related to underlying and secondary effects of malignancy",
                        "criterion": "CNS disease related to underlying and secondary effects of malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Cardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction ≤ 50% or chronic stable angina;",
                "criterions": [
                    {
                        "exact_snippets": "Cardiac history of congestive heart failure (CHF) requiring treatment",
                        "criterion": "congestive heart failure (CHF)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Cardiac history of congestive heart failure (CHF) requiring treatment",
                        "criterion": "congestive heart failure (CHF)",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ejection fraction ≤ 50%",
                        "criterion": "ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "chronic stable angina",
                        "criterion": "chronic stable angina",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Cardiac history of congestive heart failure (CHF) requiring treatment",
                                "criterion": "congestive heart failure (CHF)",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Cardiac history of congestive heart failure (CHF) requiring treatment",
                                "criterion": "congestive heart failure (CHF)",
                                "requirement": {
                                    "requirement_type": "treatment requirement",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "ejection fraction ≤ 50%",
                        "criterion": "ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "chronic stable angina",
                        "criterion": "chronic stable angina",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is known to have human immunodeficiency virus infection.",
                "criterions": [
                    {
                        "exact_snippets": "known to have human immunodeficiency virus infection",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known to have human immunodeficiency virus infection",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant agrees not to participate in another interventional study while on treatment.",
                "criterions": [
                    {
                        "exact_snippets": "agrees not to participate in another interventional study while on treatment",
                        "criterion": "participation in another interventional study",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "agrees not to participate in another interventional study while on treatment",
                        "criterion": "participation in another interventional study",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has had major surgery within 4 weeks prior to the first study dose.",
                "criterions": [
                    {
                        "exact_snippets": "major surgery within 4 weeks prior to the first study dose",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "major surgery within 4 weeks prior to the first study dose",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has disseminated intravascular coagulation abnormality (DIC).",
                "criterions": [
                    {
                        "exact_snippets": "disseminated intravascular coagulation abnormality (DIC)",
                        "criterion": "disseminated intravascular coagulation (DIC)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "disseminated intravascular coagulation abnormality (DIC)",
                        "criterion": "disseminated intravascular coagulation (DIC)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has had radiation therapy within 4 weeks prior to the first study dose.",
                "criterions": [
                    {
                        "exact_snippets": "has had radiation therapy within 4 weeks prior to the first study dose",
                        "criterion": "radiation therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "has had radiation therapy within 4 weeks prior to the first study dose",
                        "criterion": "radiation therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to the first study dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Study participants must not enter the study if any of the following exclusion criteria are met:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "2. Has clinically significant graft-versus-host-disease (GVHD) requiring treatment",
                "criterions": [
                    {
                        "exact_snippets": "clinically significant graft-versus-host-disease (GVHD) requiring treatment",
                        "criterion": "graft-versus-host-disease (GVHD)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant graft-versus-host-disease (GVHD) requiring treatment",
                        "criterion": "graft-versus-host-disease (GVHD)",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "clinically significant graft-versus-host-disease (GVHD) requiring treatment",
                        "criterion": "graft-versus-host-disease (GVHD)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant graft-versus-host-disease (GVHD) requiring treatment",
                        "criterion": "graft-versus-host-disease (GVHD)",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is defined as having morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016) and considered ineligible to receive intensive chemotherapy.",
                "criterions": [
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "primary or secondary AML"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": "morphologically documented"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "previously untreated"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "WHO criteria (2016)"
                        }
                    },
                    {
                        "exact_snippets": "considered ineligible to receive intensive chemotherapy",
                        "criterion": "eligibility for intensive chemotherapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "primary or secondary AML"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": "morphologically documented"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "previously untreated"
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented newly diagnosed previously untreated primary or secondary AML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "WHO criteria (2016)"
                        }
                    },
                    {
                        "exact_snippets": "considered ineligible to receive intensive chemotherapy",
                        "criterion": "eligibility for intensive chemotherapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Study participant has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250 milliseconds (ms).",
                "criterions": [
                    {
                        "exact_snippets": "any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (rhythm, conduction, morphology)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "third-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    },
                    {
                        "exact_snippets": "second-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "second"
                        }
                    },
                    {
                        "exact_snippets": "PR interval > 250 milliseconds (ms)",
                        "criterion": "PR interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any clinically important abnormalities in rhythm, conduction or morphology of resting ECG",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (rhythm, conduction, morphology)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "third-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    },
                    {
                        "exact_snippets": "second-degree heart block",
                        "criterion": "heart block",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": "second"
                        }
                    },
                    {
                        "exact_snippets": "PR interval > 250 milliseconds (ms)",
                        "criterion": "PR interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Has ≥ Grade 2 persistent non-hematological toxicity related to the transplant",
                "criterions": [
                    {
                        "exact_snippets": "≥ Grade 2 persistent non-hematological toxicity related to the transplant",
                        "criterion": "non-hematological toxicity related to the transplant",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≥ Grade 2 persistent non-hematological toxicity related to the transplant",
                        "criterion": "non-hematological toxicity related to the transplant",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "≥ Grade 2 persistent non-hematological toxicity related to the transplant",
                        "criterion": "non-hematological toxicity related to the transplant",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≥ Grade 2 persistent non-hematological toxicity related to the transplant",
                        "criterion": "non-hematological toxicity related to the transplant",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant must meet the following criteria as indicated on the clinical laboratory tests:",
                "criterions": [
                    {
                        "exact_snippets": "clinical laboratory tests",
                        "criterion": "clinical laboratory test results",
                        "requirement": {
                            "requirement_type": "meets study criteria",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "clinical laboratory tests",
                        "criterion": "clinical laboratory test results",
                        "requirement": {
                            "requirement_type": "meets study criteria",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has had hematopoietic stem cell transplant (HSCT) and meets any of the following criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Study participant has had hematopoietic stem cell transplant (HSCT)",
                        "criterion": "hematopoietic stem cell transplant (HSCT)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Study participant has had hematopoietic stem cell transplant (HSCT)",
                        "criterion": "hematopoietic stem cell transplant (HSCT)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. ECOG Performance Status of 2 or 3;",
                "criterions": [
                    {
                        "exact_snippets": "ECOG Performance Status of 2 or 3",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG Performance Status of 2 or 3",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Post-menopausal (defined as at least 1 year without any menses) prior to screening, or",
                "criterions": [
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Post-menopausal (defined as at least 1 year without any menses) prior to screening",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has an active malignancy other than AML.",
                "criterions": [
                    {
                        "exact_snippets": "active malignancy other than AML",
                        "criterion": "active malignancy (excluding AML)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "active malignancy other than AML",
                        "criterion": "active malignancy (excluding AML)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria for Parts A/B/C:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria for Parts A/B/C:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "Study participants must not enter the study if any of the following exclusion criteria are met:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria for Part D:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has known active hepatitis B or C, or other active hepatic disorder.",
                "criterions": [
                    {
                        "exact_snippets": "known active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "known active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "other active hepatic disorder",
                        "criterion": "other hepatic disorder",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "known active hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "known active hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "awareness",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "other active hepatic disorder",
                        "criterion": "other hepatic disorder",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has known active hepatitis B or C, or other active hepatic disorder.",
                "criterions": [
                    {
                        "exact_snippets": "known active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "known active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "other active hepatic disorder",
                        "criterion": "other hepatic disorder",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "known active hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "known active hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "awareness",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "other active hepatic disorder",
                        "criterion": "other hepatic disorder",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria for Part D:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Study participant < 75 years has an ECOG performance status ≤ 2; study participant ≥ 75 years has an ECOG performance status 0-2.",
                "criterions": [
                    {
                        "exact_snippets": "Study participant < 75 years has an ECOG performance status ≤ 2",
                        "criterion": "age and ECOG performance status",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Study participant < 75 years has an ECOG performance status ≤ 2",
                        "criterion": "age and ECOG performance status",
                        "requirement": {
                            "requirement_type": "ECOG performance status",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "study participant ≥ 75 years has an ECOG performance status 0-2",
                        "criterion": "age and ECOG performance status",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "study participant ≥ 75 years has an ECOG performance status 0-2",
                        "criterion": "age and ECOG performance status",
                        "requirement": {
                            "requirement_type": "ECOG performance status",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Study participant < 75 years has an ECOG performance status ≤ 2",
                                "criterion": "age and ECOG performance status",
                                "requirement": {
                                    "requirement_type": "age",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Study participant < 75 years has an ECOG performance status ≤ 2",
                                "criterion": "age and ECOG performance status",
                                "requirement": {
                                    "requirement_type": "ECOG performance status",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "study participant ≥ 75 years has an ECOG performance status 0-2",
                                "criterion": "age and ECOG performance status",
                                "requirement": {
                                    "requirement_type": "age",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "study participant ≥ 75 years has an ECOG performance status 0-2",
                                "criterion": "age and ECOG performance status",
                                "requirement": {
                                    "requirement_type": "ECOG performance status",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 0,
                                                "unit": "N/A"
                                            },
                                            {
                                                "operator": "<=",
                                                "value": 2,
                                                "unit": "N/A"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.",
                        "criterion": "ova donation",
                        "requirement": {
                            "requirement_type": "prohibition period",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status \u00104 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is defined as having morphologically documented primary or secondary AML, MDS-IB2 (≥ 10% bone marrow blasts), or CMML by the World Health Organization (WHO) criteria (2016), and fulfills one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "morphologically documented primary or secondary AML",
                        "criterion": "acute myeloid leukemia (AML)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "morphologically documented primary or secondary AML",
                        "criterion": "acute myeloid leukemia (AML)",
                        "requirement": {
                            "requirement_type": "documentation method",
                            "expected_value": "morphological"
                        }
                    },
                    {
                        "exact_snippets": "MDS-IB2 (≥ 10% bone marrow blasts)",
                        "criterion": "myelodysplastic syndrome with increased blasts-2 (MDS-IB2)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "MDS-IB2 (≥ 10% bone marrow blasts)",
                        "criterion": "myelodysplastic syndrome with increased blasts-2 (MDS-IB2)",
                        "requirement": {
                            "requirement_type": "bone marrow blasts percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "CMML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "chronic myelomonocytic leukemia (CMML)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CMML by the World Health Organization (WHO) criteria (2016)",
                        "criterion": "chronic myelomonocytic leukemia (CMML)",
                        "requirement": {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "WHO 2016"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "morphologically documented primary or secondary AML",
                                "criterion": "acute myeloid leukemia (AML)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "morphologically documented primary or secondary AML",
                                "criterion": "acute myeloid leukemia (AML)",
                                "requirement": {
                                    "requirement_type": "documentation method",
                                    "expected_value": "morphological"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "MDS-IB2 (\u001e 10% bone marrow blasts)",
                                "criterion": "myelodysplastic syndrome with increased blasts-2 (MDS-IB2)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "MDS-IB2 (\u001e 10% bone marrow blasts)",
                                "criterion": "myelodysplastic syndrome with increased blasts-2 (MDS-IB2)",
                                "requirement": {
                                    "requirement_type": "bone marrow blasts percentage",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "%"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "CMML by the World Health Organization (WHO) criteria (2016)",
                                "criterion": "chronic myelomonocytic leukemia (CMML)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "CMML by the World Health Organization (WHO) criteria (2016)",
                                "criterion": "chronic myelomonocytic leukemia (CMML)",
                                "requirement": {
                                    "requirement_type": "diagnostic criteria",
                                    "expected_value": "WHO 2016"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Must have a negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment), and",
                "criterions": [
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours prior to start of treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": [
                                "at screening",
                                "during the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has a history of Grade 3 or 4 non-hematologic toxicity related to tyrosine kinase inhibitor.",
                "criterions": [
                    {
                        "exact_snippets": "history of Grade 3 or 4 non-hematologic toxicity related to tyrosine kinase inhibitor",
                        "criterion": "non-hematologic toxicity related to tyrosine kinase inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of Grade 3 or 4 non-hematologic toxicity related to tyrosine kinase inhibitor",
                        "criterion": "non-hematologic toxicity related to tyrosine kinase inhibitor",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male study participants and their female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Male study participants ... must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "male study participant contraception use",
                        "requirement": {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "Male study participants ... must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "male study participant contraception use",
                        "requirement": {
                            "requirement_type": "contraception timing",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "female spouse/partner contraception use",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "female spouse/partner contraception use",
                        "requirement": {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "female spouse/partner contraception use",
                        "requirement": {
                            "requirement_type": "contraception timing",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.",
                        "criterion": "ova donation",
                        "requirement": {
                            "requirement_type": "prohibition period",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "prohibition period",
                            "expected_value": [
                                "from screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration.",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Female study participants must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration.",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": [
                                "at screening",
                                "during the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Study participants are considered ineligible to receive intensive chemotherapy based on their age being ≥ 75 years.",
                "criterions": [
                    {
                        "exact_snippets": "age being ≥ 75 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "age being \u001e 75 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume during the first second (FEV1) ≤ 65%;",
                "criterions": [
                    {
                        "exact_snippets": "Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65%",
                        "criterion": "diffusing capacity of the lung for carbon monoxide (DLCO)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "forced expiratory volume during the first second (FEV1) ≤ 65%",
                        "criterion": "forced expiratory volume during the first second (FEV1)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Diffusing capacity of the lung for carbon monoxide (DLCO) \u00104 65%",
                        "criterion": "diffusing capacity of the lung for carbon monoxide (DLCO)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "forced expiratory volume during the first second (FEV1) \u00104 65%",
                        "criterion": "forced expiratory volume during the first second (FEV1)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Must use an acceptable highly effective contraception starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Must use an acceptable highly effective contraception starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "acceptable highly effective contraception"
                        }
                    },
                    {
                        "exact_snippets": "Must use an acceptable highly effective contraception starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Creatinine clearance ≥ 30 mL/min to < 45 ml/min;",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance ≥ 30 mL/min to < 45 ml/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "mL/min"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 45,
                                        "unit": "mL/min"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine clearance \u001e 30 mL/min to < 45 ml/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "mL/min"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 45,
                                        "unit": "mL/min"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is suitable for oral administration of study drug and has minimum life expectancy (≥ 3 months)",
                "criterions": [
                    {
                        "exact_snippets": "suitable for oral administration of study drug",
                        "criterion": "suitability for oral administration",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "minimum life expectancy (≥ 3 months)",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "suitable for oral administration of study drug",
                        "criterion": "suitability for oral administration",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "minimum life expectancy (\u0013 months)",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. An HMA, VEN (or other BCL-2 inhibitor), a tyrosine kinase inhibitor (TKI), a FLT3 inhibitor (FLT3i), a hematopoietic stem cell transplant (HSCT), and/or a chemotherapeutic agent for antecedent myeloid neoplasm (Note: Prior chemotherapy for solid tumors considered in remission is allowed.)",
                "criterions": [
                    {
                        "exact_snippets": "An HMA, VEN (or other BCL-2 inhibitor), a tyrosine kinase inhibitor (TKI), a FLT3 inhibitor (FLT3i), a hematopoietic stem cell transplant (HSCT), and/or a chemotherapeutic agent for antecedent myeloid neoplasm",
                        "criterion": "prior treatment for antecedent myeloid neoplasm",
                        "requirement": {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "HMA",
                                "VEN (or other BCL-2 inhibitor)",
                                "tyrosine kinase inhibitor (TKI)",
                                "FLT3 inhibitor (FLT3i)",
                                "hematopoietic stem cell transplant (HSCT)",
                                "chemotherapeutic agent"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male study participants and their female spouse/partners who are of childbearing potential must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Male study participants ... must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "male study participant contraception use",
                        "requirement": {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "Male study participants ... must be using highly effective contraception starting at screening and continue throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "male study participant contraception use",
                        "requirement": {
                            "requirement_type": "contraception timing",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                "criterions": [
                    {
                        "exact_snippets": "Male study participants must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "prohibition period",
                            "expected_value": [
                                "starting at screening",
                                "throughout the study period",
                                "for 90 days after the final study drug administration"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Serum AST and ALT ≤ 3× institutional ULN unless considered due to leukemic organ involvement.",
                "criterions": [
                    {
                        "exact_snippets": "Serum AST ... ≤ 3× institutional ULN",
                        "criterion": "serum AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum ... ALT ≤ 3× institutional ULN",
                        "criterion": "serum ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless considered due to leukemic organ involvement",
                        "criterion": "leukemic organ involvement",
                        "requirement": {
                            "requirement_type": "cause of elevated AST/ALT",
                            "expected_value": "leukemic organ involvement"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Serum AST ... \u0010 3\u0010 institutional ULN",
                                    "criterion": "serum AST",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 3,
                                            "unit": "institutional ULN"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Serum ... ALT \u0010 3\u0010 institutional ULN",
                                    "criterion": "serum ALT",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 3,
                                            "unit": "institutional ULN"
                                        }
                                    }
                                }
                            ]
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "unless considered due to leukemic organ involvement",
                    "criterion": "leukemic organ involvement",
                    "requirement": {
                        "requirement_type": "cause of elevated AST/ALT",
                        "expected_value": "leukemic organ involvement"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Must have a negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment), and",
                "criterions": [
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative serum or urine pregnancy test at screening (within 72 hours prior to start of treatment)",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours prior to start of treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                "criterions": [
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v4.03 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "objective findings",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v4.03 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03) ... from prior AML, MDS-IB2, or CMML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior AML, MDS-IB2, or CMML treatment",
                        "requirement": {
                            "requirement_type": "objective findings",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation, including a chronic respiratory disease that requires continuous oxygen, or a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, or cardiovascular disease, or any other medical condition or known hypersensitivity to any of the study medications including excipients of VEN and AZA that in the opinion of the Investigator would adversely affect participating in this study.",
                "criterions": [
                    {
                        "exact_snippets": "any condition which, in the Investigator's opinion, makes the study participant unsuitable for study participation",
                        "criterion": "any condition making participant unsuitable for study participation",
                        "requirement": {
                            "requirement_type": "Investigator's opinion of suitability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic respiratory disease that requires continuous oxygen",
                        "criterion": "chronic respiratory disease requiring continuous oxygen",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, or cardiovascular disease",
                        "criterion": "significant history of disease",
                        "requirement": {
                            "requirement_type": "disease type",
                            "expected_value": [
                                "renal",
                                "neurologic",
                                "psychiatric",
                                "endocrinologic",
                                "metabolic",
                                "immunologic",
                                "hepatic",
                                "cardiovascular"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, or cardiovascular disease",
                        "criterion": "significant history of disease",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other medical condition ... that in the opinion of the Investigator would adversely affect participating in this study",
                        "criterion": "any other medical condition adversely affecting participation",
                        "requirement": {
                            "requirement_type": "Investigator's opinion of adverse effect on participation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known hypersensitivity to any of the study medications including excipients of VEN and AZA",
                        "criterion": "known hypersensitivity to study medications or excipients",
                        "requirement": {
                            "requirement_type": "hypersensitivity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Any other comorbidity that the Investigator judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor during screening and prior to treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Any other comorbidity that the Investigator judges to be incompatible with intensive chemotherapy",
                        "criterion": "comorbidity incompatible with intensive chemotherapy",
                        "requirement": {
                            "requirement_type": "compatibility with intensive chemotherapy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Any other comorbidity that the Investigator judges to be incompatible with intensive chemotherapy",
                        "criterion": "comorbidity incompatible with intensive chemotherapy",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must be reviewed and approved by the Medical Monitor during screening and prior to treatment",
                        "criterion": "review and approval by Medical Monitor",
                        "requirement": {
                            "requirement_type": "reviewed and approved",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must be reviewed and approved by the Medical Monitor during screening and prior to treatment",
                        "criterion": "review and approval by Medical Monitor",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "during screening",
                                "prior to treatment"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery).",
                "criterions": [
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v4.03 grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "objective findings",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v4.03 grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "persistent non-hematological toxicities of  Grade 2 (CTCAE v4.03), with symptoms and objective findings, from treatment for antecedent myeloid neoplasms (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, immunosuppressive therapy, radiation, or surgery)",
                        "criterion": "non-hematological toxicities from prior treatment for antecedent myeloid neoplasms",
                        "requirement": {
                            "requirement_type": "objective findings",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or study participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.",
                "criterions": [
                    {
                        "exact_snippets": "congestive heart failure New York Heart Association (NYHA) class 3 or 4",
                        "criterion": "congestive heart failure NYHA class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of congestive heart failure NYHA class 3 or 4 in the past",
                        "criterion": "history of congestive heart failure NYHA class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of congestive heart failure NYHA class 3 or 4 in the past",
                        "criterion": "history of congestive heart failure NYHA class",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "echocardiogram",
                                "multigated acquisition (MUGA) scan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "time_window",
                            "expected_value": "within 3 months prior to study entry"
                        }
                    },
                    {
                        "exact_snippets": "unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "LVEF",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Study participant is suitable for oral administration of study drug and has minimum life expectancy (≥ 3 months)",
                "criterions": [
                    {
                        "exact_snippets": "suitable for oral administration of study drug",
                        "criterion": "suitability for oral administration of study drug",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "minimum life expectancy (≥ 3 months)",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "suitable for oral administration of study drug",
                        "criterion": "suitability for oral administration of study drug",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "minimum life expectancy (\u0013e 3 months)",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Total serum bilirubin ≤ 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years; total serum bilirubin ≤ 1.5x institutional ULN (or ≤ 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants ≥ 75 years.",
                "criterions": [
                    {
                        "exact_snippets": "Total serum bilirubin ≤ 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total serum bilirubin ≤ 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total serum bilirubin ≤ 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "unless considered due to leukemic organ involvement"
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 1.5x institutional ULN (or ≤ 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 1.5x institutional ULN (or ≤ 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 1.5x institutional ULN (or ≤ 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "unless considered due to leukemic organ involvement"
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "condition",
                            "expected_value": "documented history of Gilbert's syndrome"
                        }
                    },
                    {
                        "exact_snippets": "total serum bilirubin ≤ 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants ≥ 75 years",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "unless considered due to leukemic organ involvement"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Total serum bilirubin \u0010 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                                        "criterion": "total serum bilirubin",
                                        "requirement": {
                                            "requirement_type": "age",
                                            "expected_value": {
                                                "operator": "<",
                                                "value": 75,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Total serum bilirubin \u0010 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                                        "criterion": "total serum bilirubin",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Total serum bilirubin \u0010 3x institutional ULN unless considered due to leukemic organ involvement for study participants < 75 years",
                                "criterion": "total serum bilirubin",
                                "requirement": {
                                    "requirement_type": "exception",
                                    "expected_value": "unless considered due to leukemic organ involvement"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "total serum bilirubin \u0010 1.5x institutional ULN (or \u0010 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants \u001e 75 years",
                                        "criterion": "total serum bilirubin",
                                        "requirement": {
                                            "requirement_type": "age",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 75,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "total serum bilirubin \u0010 1.5x institutional ULN (or \u0010 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants \u001e 75 years",
                                        "criterion": "total serum bilirubin",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1.5,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "total serum bilirubin \u0010 1.5x institutional ULN (or \u0010 3x institutional ULN if documented history of Gilbert's syndrome) unless considered due to leukemic organ involvement for study participants \u001e 75 years",
                                "criterion": "total serum bilirubin",
                                "requirement": {
                                    "requirement_type": "exception",
                                    "expected_value": "unless considered due to leukemic organ involvement"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "total serum bilirubin \u0010 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants \u001e 75 years",
                                                "criterion": "total serum bilirubin",
                                                "requirement": {
                                                    "requirement_type": "age",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 75,
                                                        "unit": "years"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "total serum bilirubin \u0010 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants \u001e 75 years",
                                                "criterion": "total serum bilirubin",
                                                "requirement": {
                                                    "requirement_type": "condition",
                                                    "expected_value": "documented history of Gilbert's syndrome"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "total serum bilirubin \u0010 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants \u001e 75 years",
                                        "criterion": "total serum bilirubin",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "total serum bilirubin \u0010 3x institutional ULN if documented history of Gilbert's syndrome ... for study participants \u001e 75 years",
                                "criterion": "total serum bilirubin",
                                "requirement": {
                                    "requirement_type": "exception",
                                    "expected_value": "unless considered due to leukemic organ involvement"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Study participants ≥ 75 years of age are considered ineligible to receive intensive chemotherapy if they meet any of the following criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Study participants ≥ 75 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Study participants \u00003e= 75 years of age",
                    "criterion": "age",
                    "requirement": {
                        "requirement_type": "minimum",
                        "expected_value": {
                            "operator": ">=",
                            "value": 75,
                            "unit": "years"
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Study participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or study participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.",
                "criterions": [
                    {
                        "exact_snippets": "congestive heart failure New York Heart Association (NYHA) class 3 or 4",
                        "criterion": "congestive heart failure NYHA class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 4,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of congestive heart failure NYHA class 3 or 4 in the past",
                        "criterion": "history of congestive heart failure NYHA class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 4,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": [
                                "echocardiogram",
                                "multigated acquisition (MUGA) scan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 3 months prior to study entry"
                        }
                    },
                    {
                        "exact_snippets": "screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "LVEF value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 30 mL/min for study participants < 75 years; creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 45 mL/min for study participants ≥ 75 years.",
                "criterions": [
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 30 mL/min for study participants < 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "Cockcroft-Gault formula",
                                "24-h urine collection"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 30 mL/min for study participants < 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 30 mL/min for study participants < 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 45 mL/min for study participants ≥ 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "Cockcroft-Gault formula",
                                "24-h urine collection"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 45 mL/min for study participants ≥ 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance as calculated by the Cockcroft-Gault formula or measured by 24-h urine collection of ≥ 45 mL/min for study participants ≥ 75 years",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}